PDCD1 and neoplasm: Additionally, combination therapy enhanced in vivo cytotoxicity against C4–2 cells, leading to decreased tumor volume and longer survival in NOD/SCID mice, by directly blocking the PD-L1/PD-1 axis in both NK cells and CD8+ T cells (118).